January/February

Emerging Therapies for Hemophilia A and B

January 22, 2019

Clinical Insights

Although the leading treatment for hemophilia is a replacement therapy in the form of both plasma-derived and rF products, research is underway for the discovery of novel agents.

Approvals and Access Highlight the Year Ahead in Specialty

January 22, 2019

From the Chairman

Following a year in which nearly 40 specialty drugs were approved by the FDA, 2019 also is expected to be huge in the specialty market, with more therapies for cancer, multiple sclerosis, and orphan conditions on the horizon.